Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079

Niels van de Donk • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Antibodies Carfilzomib Isatuximab MOR202 Pomalidomide TAK-079

Following the success of daratumumab, a range of other anti-CD38 antibodies are being investigated for multiple myeloma (MM). Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses three new such antibodies: isatuximab, MOR202 and TAK-079. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals